toid arthritis patients. toid arthritis and physical function in rheuma signifi cantly improved diseaseactivity olokizumab blocker IL-6 trial demonstrated thatthe novel Results from the phase 3CREDO-1 in RA significant improvements Olokizumab shows
read more on PEER-REVIEWED Medicom InternationalConference SeriesinRheumatology CONFERENCE REPORT Medicom Podcast 2020 EULAR Check outthe P AGE 4 - - Editor pegol treatment. disease activity with certolizumab rate and axialspondyloarthritis flare AAU of reductions significant The phase 4C-VIEWtrial showed uveitis reduces acuteanterior axSpA: certolizumab pegol EULAR E-Congress 2020 Prof. Dennis McGongale,University ofLeeds,UnitedKingdom read more on P AGE 7 Virtual CongressVirtual European League AgainstRheumatism responding to non-bDMARD. sion of patientsinadequately inhibited radiographic progres- function, pain,and fatigue and letal symptoms,physical psoriasis, fast improvements in musculoske- SELECT-PsA-1: upadacitinib showed in PsAwithupadacitinib Fast onsetofimprovement read more on 3-6 JUNE 2020 P AGE 11 Contents
Letter from the Editor
3 Rheumatoid Arthritis 3 Low DAS at 4 months predicts sustained DMARD-free remission 4 Olokizumab significantly improves RA features and patient- reported outcomes COLOPHON 5 New nanoparticle promising future agent in RA 5 Immune-related AEs due to checkpoint inhibitors require care Editor Prof. Dennis McGonagle coordination University of Leeds, UK 6 Preliminary findings suggest rozibafusp alfa effective and Advisory Board Dr Agna Neto Hospital Central do Funchal, Madeira; tolerable in RA Chronic Diseases Research Center (CEDOC), 7 Ankylosing Spondylitis NOVA Medical School, Portugal 7 TNF-α inhibitors improve bone mineral density in AS patients Publishing Director Paul Willers 7 Certolizumab pegol reduces acute anterior uveitis in axial Editorial Manager Lisa Colson spondyloarthritis Editorial Coordinators Dr Joery Goossens 8 AxSpA real-life remission rates higher on biologics Sanne Lauriks Medical Writer Constance de Koning 9 Worse response axSpA patients to second TNFi versus first TNFi Production Manager Desiree Heijl 9 Reduced maintenance dose of certolizumab pegol can be used in Graphic Design MOOZ grafisch ontwerp axSpA Layout In het Houten Paard 10 Psoriasis and Psoriatic Arthritis ISSN 2468-8762 20:6 10 Secukinumab monotherapy as efficient as adalimumab All rights reserved. 11 Upadacitinib provides fast onset of improvement in psoriatic No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other arthritis electronic or mechanical methods, without the prior written permission of 13 Adalimumab added to methotrexate yields better results in PsA the publisher, except in the case of brief quotations embodied in critical reviews and certain other noncommercial uses permitted by copyright law. than methotrexate escalation Copyright ©2020 Medicom Medische Uitgeverij BV 13 Ixekizumab shows sustained improvements in pain and fatigue at 3 years Disclaimer: Our independent peer-reviewed Medicom Conference Reports are made 14 Osteoporosis and Osteoarthritis possible by sponsoring. The ideas and opinions expressed in this journal or other associated publications do not necessarily reflect those of Medicom 14 Positive effect denosumab on fall risk Medical Publishers. Although great care has been taken in compiling the content of this publication, Medicom is not responsible or liable in 15 Hydroxychloroquine not effective in patients with hand any way for the currency of the information, for any errors, omissions or osteoarthritis inaccuracies in the original articles, or for any consequences arising from the content. Products mentioned in this report may not be covered by 15 Higher mortality risk with tramadol versus NSAIDs for marketing authorisation in some countries. Product information, applicable in your country, should be reviewed before prescribing. The mention of any osteoarthritis patients product, service, or therapy in this publication should not be construed as an endorsement of the products mentioned. It is the responsibility of the 17 Systemic Sclerosis and Systemic Lupus Erythematosus treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages 17 Composite endpoint CRESS for primary Sjogren’s syndrome and the best treatment for the patient. Readers are advised to check the appropriate medical literature and the product information currently 17 Wide variation in prescription and dosing patterns for provided by the manufacturer of each drug to be administered to verify hydroxychloroquine in SLE the dosage, method, and duration of administration, or contraindications. Readers are also encouraged to contact the manufacturer with questions 18 Subclinical myocardial involvement progresses in SSc patients about the features or limitations of any products. Medicom assumes no responsibility for any injury or damage to persons or property arising out of 19 Anifrolumab achieves rapid and durable BICLA-response or related to any use of the material contained in this publication or to any 20 COVID-19 errors or omissions. 20 COVID-19 and inflammatory rheumatic disease: some key issues
Head Office Postal address Medicom Medical Publishers Medicom Medical Publishers Faas Eliaslaan 5 PO Box 90 3742 AR Baarn 3740 AB Baarn The Netherlands The Netherlands